Covid19 Clinical Trial
Official title:
How Brazilian Chiropractors Are Being Affected and What Strategies They Have Developed for Facing the COVID-19 Pandemic
Brazil has the Latin America's largest coronavirus outbreak, numbers second only to the
United States in the western hemisphere. The first COVID-19 confirmed case in Brazil was on
February of 2020. A 61yrs old man tested positive after returning from a trip to Italy. Few
other very first cases were also imported from Europe by returning travelers. The first
locally transmitted case was registered on March of 2020, when a total of 8 cases have
already been confirmed. At the time the WHO declares the outbreak as a pandemic (March 11)
Brazil had 52 confirmed cases being 6 of those locally transmitted.
Healthcare professionals are now more important than ever. Given the intrinsic nature of the
hands-on treatment of the Chiropractic profession, it is extremely important to understand
what strategies chiropractors have put in place to address patient care, safety, and self
report COVID contamination of those professionals.
| Status | Not yet recruiting |
| Enrollment | 948 |
| Est. completion date | September 18, 2020 |
| Est. primary completion date | September 6, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Chiropractors graduated from national or international accredited colleges. Exclusion Criteria: - Chiropractors who did not treated patients in 2020. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Trate - Tratamentos Especializados |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | What measures have been implemented to avoid SARS-COV2 transmission when taking care of patients, during the COVID-19 pandemic. | Subjects will answer a online survey addressing what measures they have implemented to prevent SARS-COV2 contamination among staff and patients, when taking care of patients. These questions address the use of individual protection devices, sanitizing methods, social distancing, patient orientation, and consultation time. These will be analyzed in conjunct, using descriptive statistics. | 2 weeks | |
| Secondary | Professionals SARS-COV2 infection rates. | Self declared SARS-COV2 infection rates. | 2 weeks | |
| Secondary | Professional financial impact. | To assess the potential professional financial impact caused by the pandemic, the subjects will answer a question in the survey addressing if they have had a financial loss during the pandemic. This question will have the following answer options: no financial loss, less than 25% financial loss, between 25-50%, between 50-75%, more than 75% of financial loss due the pandemic. | 2 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |